Terumo Corporation has officially begun the liquidation of its Dutch subsidiary, Quirem Medical B.V., effective June 27, 2025. The decision marks the end of Quirem’s production of radiation-emitting beads used in catheter-based liver cancer treatments, a move influenced by significant market and regulatory challenges.
Quirem Medical, acquired by Terumo in 2020, introduced innovative radiation-emitting beads to the European interventional oncology market. Despite initial success, expanding beyond Europe proved difficult due to varying regulatory landscapes and rising competition. These obstacles hindered the anticipated growth, prompting Terumo to cease sales and initiate closure discussions with the subsidiary’s Works Council in May 2025.
Impact on Interventional Oncology
The liquidation of Quirem Medical signals a strategic shift for Terumo within the interventional oncology sector. While stepping away from the radiation-emitting beads segment, Terumo remains dedicated to advancing other therapeutic options. The company plans to continue developing microcatheters, embolic beads, drug-eluting beads, and resorbable drug-eluting beads to enhance treatment efficacy and patient outcomes for liver cancer.
Future Strategic Directions
Terumo’s commitment to innovation in medical technology remains unwavering. By reallocating resources from Quirem Medical, the company aims to strengthen its portfolio in high-potential areas of interventional oncology. This realignment is expected to drive future growth and maintain Terumo’s position as a leader in global healthcare solutions.
- Regulatory barriers significantly impeded Quirem’s global expansion efforts.
- Increased competition in the interventional oncology market reduced Quirem’s market share.
- Terumo’s strategic focus is shifting towards more promising areas within interventional oncology.
Terumo Corporation’s decision to liquidate Quirem Medical underscores the complexities of global market expansion in the medical technology sector. Regulatory differences and competitive pressures can heavily influence the success of specialized medical products. Terumo’s proactive approach in reallocating resources demonstrates a commitment to resilience and adaptability in a rapidly evolving industry.
By discontinuing Quirem Medical’s operations, Terumo is not retreating from interventional oncology but rather recalibrating its strategy to focus on more viable and innovative solutions. This move ensures that Terumo continues to provide cutting-edge medical technologies that meet the evolving needs of healthcare providers and patients worldwide.
As Terumo navigates these changes, stakeholders can expect enhanced focus on product development and market strategies that align with global regulatory standards and competitive dynamics. This strategic realignment positions Terumo to better serve the oncology community and maintain its leadership in medical technology innovation.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
